People: Bellerophon Therapeutics Inc (BLPH.OQ)
22 Aug 2019
Dr. Reinilde Heyrman, M.D., is Vice President, Chief Clinical Development Officer and Secretary of Bellerophon Therapeutics LLC, since February 2014. Prior to joining us, Dr. Heyrman served as Vice President, Chief Clinical Development Officer of Ikaria from March 2012 to February 2014. Dr. Heyrman held several positions at Daiichi Sankyo Pharma Development, a pharmaceutical company, from 2005 to March 2012, most recently as Vice President, Clinical Development from 2009 to March 2012. From 2001 to 2002 and 2002 to 2005, Dr. Heyrman served as Director Clinical Research and Senior Director Clinical Research, respectively, at Sankyo Pharma Development, a pharmaceutical company. Dr. Heyrman received an M.D. from the University of Antwerp, Belgium.
|Total Annual Compensation, USD||655,528|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||79,246|
|Fiscal Year Total, USD||734,774|